1) CanniMed Therapeutics is an international, biopharmaceutical company and leader in the Canadian medical cannabis industry with pharmaceutical-grade products. 2) They have a 15-year history of growing medical cannabis and a first mover advantage in emerging international markets like Australia. 3) Recent results show strong revenue, volume, and EBITDA growth and they have expanded production capacity with government support. The Canadian and international medical cannabis markets provide significant opportunities.

1. JUNE 2017
Leader in Canadian Medical Cannabis
and International First Mover

2. DISCLAIMER
GENERAL
This documentation is a presentation of general background information about the activities of CanniMed Therapeutics Inc. (the “Company”, “CMED”, “us” or “we”). The information contained in this presentation is derived
solely from otherwise publicly available information concerning CMED and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an
investment in CMED.
This presentation does not constitute or form part of any offer or invitation for the sale or purchase of securities or any of the assets, business or undertaking described herein nor shall it or any part of it form the basis of
or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this presentation who are considering acquiring securities of CMED are reminded that
any such purchase or subscription must not be made on the basis of the information contained in this presentation but are referred to the continuous disclosure documents of CMED filed on SEDAR at www.sedar.com.
The contents of this presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal,
financial or tax advice.
No representation or warranty, express or implied, is made or given by or on behalf of CMED or any of its affiliates or subsidiary undertakings or any of the directors, officers or employees of any such entities as to the
accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this presentation,
CMED does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation
that may become apparent. No person has been authorised to give any information or make any representations other than those contained in this presentation and, if given and/or made, such information or
representations must not be relied upon as having been so authorised. The information and opinions contained in this presentation are provided as at the date of this presentation.
In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of CMED or any other entity
contained in this presentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of CMED or such entities.
This presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Distribution of this presentation may be restricted
or prohibited by law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CMED does not accept liability to any person in relation thereto.
FORWARD-LOOKING INFORMATION
This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and
may include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our
expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified by
the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”, “believes”, or variations of such words and phrases or
state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other
characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations,
estimates and projections regarding future events or circumstances.
Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends,
current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-
looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.
Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors
not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this
presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should
not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of this
presentation or the date indicated, regardless of the time of delivery of the presentation. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a
result of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking information contained in this presentation is expressly qualified by the
foregoing cautionary statements.
NON-IFRS MEASURES AND INDUSTRY METRICS
This presentation makes reference to certain non-IFRS measures including “EBITDA” and “Adjusted EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have a
standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement
those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of
our financial information reported under IFRS. Please refer to the Prospectus for further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.
2

3. SUMMARY OVERVIEW
CanniMed Therapeutics Inc.
3
An international, biopharmaceutical company and
a leader in the Canadian cannabis industry with
best-in-class pharmaceutical-grade cannabis
products and a first mover advantage in rapidly
emerging international markets

4. Experienced LP with a 15 year history of growing medical cannabis
INVESTOR HIGHLIGHTS
Pharmaceutical
-Grade; GMP-
compliant;
investing in
clinical trials
The Canadian
medical market is
First mover
Strong management
and board
with broad experience in
cannabis, medical biotechnology,
and pharmaceuticals
4
Significant
Revenue, EBITDA
and Volume
Growth
to address the massive
advantage and
best positioned
international
market opportunity
here and now
with growing acceptance;
increasing evidence of
effectiveness; Baby Boomers are
a significant market opportunity

5. Recent
Developments
Strong 1H 2017
results
KG SOLD
(+77.2% H/H)
ADJUSTED EBITDA
(+$1.2MM H/H)
REVENUE
(+78.1% H/H)
Entered into Canada’s First Exclusive
Pharmacy Distribution Agreement for
Medical Cannabis
Commenced $10.5MM Cannabis Oils
Facility Expansion with Support of the
Saskatchewan Provincial Government
Agreement with CTT Pharmaceutical
Holdings Inc. (“CTT”) to License its Orally
Dissolvable Thin Film Wafer
5
Completed oils exports to Australia and
Cayman Islands and received follow-up
order for 360,000 ml of CanniMed® oils
to Australia

6. Pharmaceutical Cannabis
6
THE OPPORTUNITY IS SIGNIFICANT
Increased risk
of addiction,
overdose and
mortality
A strong need
for alternative
methods for pain
management
Seeking pain relief
and maintaining an
active lifestyle and
manage end-of-life
conditions
Legislative, political
environments are
more favorable
towards medical
cannabis globally
Commonly
prescribed opioids
Increasing
healthcare costs
Rapidly aging
population
Canada
is a leader

7. Here and Now
7
THE CANADIAN MEDICAL MARKET
2015 Q1 16 Q2 16 Q3 16
6,704
584
8,807
11,473
14,373
2,084
4,504
Herbal (kg)
Q/Q growth in
Registered Patients
32%
8% Q/Q growth
in Herbal
70% Q/Q growth in Oil
Cannabis oils have greatly accelerated market growth
7
Cannabis Oil (kg)
(1) Rolling 12 months. Shown as at the end of the reporting period. Includes wholesale sales.
Q4 16
14,373
17,026
8,613

8. BABY BOOMERS
To Provide a Step-Change in Demand
8
(1) Pain Resource Centre, 2015: Pain in Canada Fact Sheet (2) Canadian Pain Society. (3) Direct costs. Pain Resource Centre, 2015: Pain in Canada Fact Sheet. (4) The Canadian
Pain Society, 2011: Call to Action: The Need for a National Pain Strategy for Canada. (5) Globe and Mail, October 2014. (6) Canadian Centre on Substance Abuse, July 2015.
$2
$193
2015
2010
21.7
2015
2010
1 in 5
Canadian
adults suffer
from chronic
pain(2)
Chronic
pain costs
more than
$6 billion
annually(3)
Inadequate pain
assessment and
treatment is a
growing problem
in Canada(4)
Opioids are
prescribed for
chronic pain
despite little
evidence of long
term efficacy(5)
With an aging
population, the
incidence of
chronic pain
increases(1)
29%of the Canadian
population
16% of seniors use opioids(6)
New delivery mechanisms such
as cannabis oils and gelcaps are
ideally suited:
• More traditional forms
• Easier to target symptoms/doses
• Avoid stigmas associated
with smoking

9. INTERNATIONAL MARKETS
Opportunities are Exploding
9
International markets are opening very quickly
for pharma-quality products
9
Cayman Islands
Fulfilled order of
12,960ml of Oils to
the Cayman Islands
United States
Ownership of GMP
compliant production facility
with potential to support
over 50,000kg of capacity
per annum
In process of applying
to the DEA for a licence
DEA to allow for increased
supply for research purposes
Australia
Completed the first ever
shipment of commercial
cannabis oil and received
three subsequent orders for
360,000ml of Oil products
Worldwide population of baby
boomers is over 1.1 billion
~121.4 Million
Europe
baby boomers
~73.8 Million
U.S
baby boomers
~5.0 Million
Australia
baby boomers
European Union
Entered into a LOI with Creso Pharma Ltd.
for the purpose of marketing CMED
Medical Cannabis Brands

10. GMP Compliant
Extensive quality
control
Precision growing
and extraction
No pesticides
CanniMed is focused on
producing high-quality
products that are best
positioned in any market
Well Positioned for
the near and long term
10
CANNIMED THERAPEUTICS
(1) GMP are standards and procedures that pharmaceutical
companies must adhere to in manufacturing their products in North
America; part of quality assurance that ensures that drugs are
consistently produced and controlled to meet quality standards
FRAMEWORK STILL TBD
Recreational
Medical
Product
will be key
differentiation
CMED
Provide significant opportunity
best-in-class oils
– particularly in consumables
High margin
New delivery mechanisms
provide opportunities for IP
distributionPharmacy
will be a game changer
to international markets
Only pathway
OPPORTUNITY IS NOW

11. Herbal
CANNIMED PRODUCT OFFERING
Pharmaceutical-quality and branding
promotes doctor confidence and supports
more effective prescription dosages
Identified by the
percentage of THC
and CBD they
contain
Each product is designed with
specific benefits in mind to
address each patient’s
requirements
Purple 1·13
0.7% THC
13.0% CBD
Red 4·10
4.0% THC
10.0% CBD
Orange 9·9
9.0% THC
9.5% CBD
Yellow 12·0
12.5% THC
<0.5% CBD
Green 15·5
15.0% THC
5.0% CBD
Blue 17·1
17.0% THC
0.7% CBD
Indigo 22·1
22.0% THC
0.7% CBD
11

12. Oils
CANNIMED PRODUCT OFFERING
For patients reluctant to smoke herbal product
• Ideal for palliative care and hospitalized patients
• Significant sales acceleration since launching oils in Q1 2016
For baby boomers looking for a safe,
reliable way to manage their chronic pain
symptoms and maintain an active lifestyle
PRODUCTION Ramp 2H 2017CANNABIS OILS
Higher margin, value-added products with
Purple 1·20
0.7
20.0
60
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg1,200
Orange 10·10
9.8
9.9
588
TOTAL CBD mg594
THC mg/ml
CBD mg/ml
THC mg
Blue 18·0
18.3
0.2
1,098
12
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg
12
global market appeal
GEL CAPS

13. adding 5,000 kg additional capacity in 2018
Saskatoon, Saskatchewan
13
GMP-COMPLIANT PRODUCTION FACILITIES
(1) Benefited from the technologies and innovations advanced over the course of seven distinct facility builds.
Good Production
Practices (GPP)
Required under ACMPR
International
Organization for
Standardization (ISO)
GMP Standards
Only LP deemed by Health
Canada to be compliant
Required for pharmaceutical
production
GMP
97,000 sq. ft.
above-ground production facility
30 large individual biosecure growth chambers
7,000 kg current capacity;
State-of-the-art, GMP-compliant
5 separate Level 7 “Seventh
Generation”
facility(1)
production process
MOST RIGOROUS
RIGOROUS
LEAST RIGOROUS
security compliant
vaults
Above ground facility on 100 acres,
currently using approximately 20 acres

14. Clinical Trials
1414
• “CAPRI Trial”(1)
- First Phase II Health Canada approved clinical
trial using cannabis ($1 million invested)
- Randomized, double-blind, placebo
controlled, proof-of-concept Phase IIA clinical
trial
- Seeks to examine the varying ratios of THC and
CBD in patients with osteoarthritis of the knee
• “Identifying the molecular mechanisms involved
in suppressing multiple sclerosis induced
neuropathic pain following cannabinoid
treatment in an animal model of multiple
sclerosis” the Company’s pre-clinical study
partnered with Dr. Namaka at the University of
Manitoba.
• “CARE-E Trial” in patients with refractory pediatric
epilepsy, partnered with Dr. Richard Huntsman at
the University of Saskatchewan.
• “PICATE Trial” in patients with Tourette’s
syndrome, partnered with Dr. Paul Sandor at
Toronto Western Hospital.
(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee
Investing in Medical Care

15. Growing Momentum
REVENUE AND GROWTH
(1) Includes both dried herbal and oils1515
Total Dried Equivalents
(KG)(1)
Oil Equivalent
(KG)
341.3
403
229
714
49
% of Revenue
18.9% 45.1%
1H 2016 1H 2017H1 2016
Patients Physicians
25,991
10,224
2,385
H1 2017
3,840

16. s
Historical Financials
16
REVENUE AND GROWTH
(1) Financial results as of Q1 ending January 31, 2017; (2) Includes MMPR
Achieved
Aggressively expanding
infrastructure to meet
accelerating market demand
Total Revenue(1)(2) Oil Revenue (1)(2)
Experiencing
Rapid Sales
Growth
32%of kg Sold
in 1H 2017
Cannabis Oils
of $0.2MM in 1H 2017
positive adj. EBITDA Launching oils in Q1 2016 has accelerated
growth and expanded opportunities for
new customers
Introduction of pharmaceutical-grade
in Canada and internationally
gel caps anticipated to accelerate growth
2015
98.2% Margin
2016
83.7% Margin
LTM
80.7% Margin
1H 2016 1H 2017
$5.8 $5.7
$9.8
$8.2
$12.9
$8.9
$4.0 $3.5
$7.1
$4.1

17. Capitalization
REVENUE AND GROWTH
17 (1) As of close of June 12, 2017; shares outstanding as of Q2 Year-End: 22,670,933
OCTOBER 31, 2016
FISCAL YEAR-END ($M)
April 30, 2017
Q2 ($M)
CASH 2.0 59.0
TOTAL CURRENT ASSETS 14.7 72.1
CURRENT LIABILITIES 7.8 6.1
DEBT 29.6 17.7
SHAREHOLDERS EQUITY 10.6 91.8
CURRENT MARKET CAPITALIZATION
(June 12, 2017)
$196.8(1)
CURRENT ENTERPRISE VALUE $155.5(1)

18. Strong Management Team and Board
18
KEY MANAGEMENT
President & CEO
Brent H. Zettl
• President of CanniMed since 1991
• Spearheaded the development activities of the
innovative underground growth chambers
• 2014 E&Y Entrepreneur of the Year for the
Prairies Business-to-Consumer category
CFO
John Knowles
• Over 30 years experience in senior executive and
board roles in Canada and internationally
• A Director of CanniMed for over eight years and past
Chair of the Audit and Finance Board Committee
• Former VP, CFO of Hudbay Minerals Inc., Executive VP
of Aur Resources Inc., and CEO of LiCo Energy Metals
Inc.
Chief Research Officer
Larry Holbrook
• Background includes Senior Research Scientist
positions with extensive and diverse agricultural
biotechnology experience in both government
and industrial settings
• Over 20 years of experience in basic research and
applications to genetic modification of crop plants
• Author or co-author on 40 publications and books
VP, Business Development and Regulatory Affairs
Gulwant Bajwa
• Previously with Health Canada as a Senior Program
Manager in former Bureau of Medical Cannabis
and as a Policy Analyst in the Intellectual Property
and Technology Transfer office of Health Canada
• Five years as Director of Operations at JDS
Uniphase Corporation

19. Strong Management Team and Board
19
BOARD OF DIRECTORS
LL.B, B.A. (Chairman)
Donald Ching
Director, Golden Opportunities Fund;
Former President and CEO of SaskTel
Doug Banzet
CFO and Director, Golden
Opportunities Fund
B.B.A.
Rob Duguid
Partner, PFM Capital; VP, Prairie
Ventures Fund
Ph.D.
Marianne Greer
Independent Pharmacist Consultant
B.Sc.
Richard Hoyt
VP, Business Development,
Mallinckrodt PLC
B.Comm, C.P.A., C.A.
Dwayne L. Lashyn
VP, Quantico Capital Corp.
Ph.D., J.D.
Bruce F. Mackler
Consultant in FDA, USDA and EPA
Regulatory Processes
Ph.D.
Brandon J. Price
Executive VP, Nascent Biotech;
Co-founder, Biogenin
B.Comm, C.P.A., C.A.
John L. Knowles
CFO and Director,
CanniMed Therapeutics Inc.
Brent Zettl
President, CEO and Director,
CanniMed Therapeutics Inc.
B.S.AB.B.A.